DAWN Stock Forecast 2025-2026
Distance to DAWN Price Targets
DAWN Price Momentum
10 Quality Stocks Worth Considering Now
Researching Day One (DAWN) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on DAWN and similar high-potential opportunities.
Latest DAWN Stock Price Targets & Analyst Predictions
Based on our analysis of 10 Wall Street analysts, DAWN has a bullish consensus with a median price target of $32.00 (ranging from $24.00 to $36.00). The overall analyst rating is Strong Buy (8.7/10). Currently trading at $8.12, the median forecast implies a 294.1% upside. This outlook is supported by 8 Buy, 1 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Andres Maldonado at HC Wainwright & Co., projecting a 343.3% upside. Conversely, the most conservative target is provided by Alec Stranahan at B of A Securities, suggesting a 195.6% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
DAWN Analyst Ratings
DAWN Price Target Range
Latest DAWN Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for DAWN.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Mar 25, 2025 | Goldman Sachs | Andrea Tan | Buy | Maintains | $27.00 |
| Mar 5, 2025 | JP Morgan | Anupam Rama | Overweight | Maintains | $34.00 |
| Feb 26, 2025 | Wedbush | Robert Driscoll | Outperform | Reiterates | $32.00 |
| Feb 26, 2025 | HC Wainwright & Co. | Andres Maldonado | Buy | Maintains | $36.00 |
| Feb 26, 2025 | Needham | Ami Fadia | Buy | Reiterates | $32.00 |
| Feb 10, 2025 | Goldman Sachs | Andrea Tan | Buy | Maintains | $43.00 |
| Jan 13, 2025 | Needham | Ami Fadia | Buy | Reiterates | $33.00 |
| Jan 7, 2025 | B of A Securities | Alec Stranahan | Buy | Maintains | $25.00 |
| Dec 17, 2024 | Jones Trading | Buy | Maintains | $34.00 | |
| Oct 31, 2024 | Needham | Ami Fadia | Buy | Reiterates | $33.00 |
| Oct 31, 2024 | HC Wainwright & Co. | Andres Maldonado | Buy | Reiterates | $40.00 |
| Oct 9, 2024 | Needham | Ami Fadia | Buy | Maintains | $33.00 |
| Aug 6, 2024 | JP Morgan | Anupam Rama | Overweight | Maintains | $36.00 |
| Aug 1, 2024 | HC Wainwright& Co. | Buy | Reiterates | $0.00 | |
| Aug 1, 2024 | B of A Securities | Alec Stranahan | Buy | Upgrade | $24.00 |
| Aug 1, 2024 | HC Wainwright & Co. | Andres Maldonado | Buy | Reiterates | $40.00 |
| Jul 31, 2024 | Needham | Ami Fadia | Buy | Maintains | $32.00 |
| Jul 30, 2024 | Needham | Ami Fadia | Buy | Reiterates | $33.00 |
| Jul 26, 2024 | HC Wainwright & Co. | Andres Maldonado | Buy | Reiterates | $40.00 |
| Jul 8, 2024 | Piper Sandler | Joseph Catanzaro | Overweight | Maintains | $40.00 |
Day One Biopharmaceuticals, Inc. (DAWN) Competitors
The following stocks are similar to Day One based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Day One Biopharmaceuticals, Inc. (DAWN) Financial Data
Day One Biopharmaceuticals, Inc. has a market capitalization of $839.22M with a P/E ratio of -8.0x. The company generates $131.16M in trailing twelve-month revenue with a -72.8% profit margin.
Revenue growth is -68.8% quarter-over-quarter, while maintaining an operating margin of -223.7% and return on equity of -22.5%.
Valuation Metrics
Growth & Margins
Financial Health
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
Day One Biopharmaceuticals, Inc. (DAWN) Business Model
About Day One Biopharmaceuticals, Inc.
Develops innovative therapies for pediatric cancer.
The company operates in the biotechnology sector, focusing on small molecule therapeutics specifically for children with cancer. Day One Biopharmaceuticals generates revenue by developing and commercializing its oncology drug candidates, leveraging collaborations with leading cancer centers to enhance its research capabilities.
Day One is committed to addressing unmet medical needs in pediatric oncology, utilizing a rapid product development strategy. This positions the company as a potential leader in a niche yet critical segment of the healthcare industry, offering investors an opportunity in a transformative market.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
181
CEO
Dr. Jeremy Bender M.B.A., Ph.D.
Country
United States
IPO Year
2021
Website
dayonebio.comDay One Biopharmaceuticals, Inc. (DAWN) Latest News & Analysis
Day One Biopharmaceuticals, Inc. (NASDAQ: DAWN) will hold its Q4 2024 Earnings Conference Call on February 25, 2025, at 4:30 PM ET, featuring key company executives and analysts.
The earnings call provides insights into Day One Biopharmaceuticals' financial performance and strategic direction, crucial for assessing investment potential and market confidence.
Day One Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Progress
1 month agoQ4 2024 net revenues for OJEMDA™ (tovorafenib) reached $29.0 million, contributing to full-year revenues of $57.2 million.
Strong Q4 and annual revenue growth for OJEMDA™ indicates solid market demand, potentially boosting investor confidence and impacting stock performance positively.
Day One Biopharmaceuticals (DAWN) reported a quarterly loss of $0.69 per share, exceeding the Zacks estimate of a $0.35 loss, and worsening from a $0.64 loss per share last year.
Day One Biopharmaceuticals' larger-than-expected quarterly loss signals potential operational or market challenges, which may negatively impact investor sentiment and stock performance.
Does Day One Biopharmaceuticals (DAWN) Have the Potential to Rally 193.16% as Wall Street Analysts Expect?
1 month agoAnalysts' price targets for Day One Biopharmaceuticals (DAWN) suggest a potential 193.2% upside, supported by a consensus increase in earnings estimates.
Analysts' price targets suggest significant upside for Day One Biopharmaceuticals, indicating potential growth. Increased earnings estimates further bolster positive sentiment.
New Strong Buy Stocks for February 13th
1 month agoSYF, SSB, VCYT, DAWN, and FISI have received a Zacks Rank #1 (Strong Buy) as of February 13, 2025.
Zacks Rank #1 indicates strong potential for these stocks, suggesting likely price appreciation, which can attract investors seeking growth opportunities.
Day One to Report Fourth Quarter and Full-Year 2024 Financial Results Tuesday, February 25, 2025
1 month agoDay One Biopharmaceuticals (Nasdaq: DAWN) will hold a live conference call and webcast on February 25, 2025, at 4:30 p.m. to discuss developments in targeted therapies.
The conference call may provide insights into Day One Biopharmaceuticals' pipeline and financial health, influencing market sentiment and stock valuation.
Frequently Asked Questions About DAWN Stock
What is Day One Biopharmaceuticals, Inc.'s (DAWN) stock forecast for 2025?
Based on our analysis of 10 Wall Street analysts, Day One Biopharmaceuticals, Inc. (DAWN) has a median price target of $32.00. The highest price target is $36.00 and the lowest is $24.00.
Is DAWN stock a good investment in 2025?
According to current analyst ratings, DAWN has 8 Buy ratings, 1 Hold ratings, and 0 Sell ratings. The stock is currently trading at $8.12. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for DAWN stock?
Wall Street analysts predict DAWN stock could reach $32.00 in the next 12 months. This represents a 294.1% increase from the current price of $8.12. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Day One Biopharmaceuticals, Inc.'s business model?
The company operates in the biotechnology sector, focusing on small molecule therapeutics specifically for children with cancer. Day One Biopharmaceuticals generates revenue by developing and commercializing its oncology drug candidates, leveraging collaborations with leading cancer centers to enhance its research capabilities.
What is the highest forecasted price for DAWN Day One Biopharmaceuticals, Inc.?
The highest price target for DAWN is $36.00 from Andres Maldonado at HC Wainwright & Co., which represents a 343.3% increase from the current price of $8.12.
What is the lowest forecasted price for DAWN Day One Biopharmaceuticals, Inc.?
The lowest price target for DAWN is $24.00 from Alec Stranahan at B of A Securities, which represents a 195.6% increase from the current price of $8.12.
What is the overall DAWN consensus from analysts for Day One Biopharmaceuticals, Inc.?
The overall analyst consensus for DAWN is bullish. Out of 10 Wall Street analysts, 8 rate it as Buy, 1 as Hold, and 0 as Sell, with a median price target of $32.00.
How accurate are DAWN stock price projections?
Stock price projections, including those for Day One Biopharmaceuticals, Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
